In Projects 1-3, the investigators will analyze the elements of the innate responses induced in the presenceof flagellin or the viral vaccine vectors; develop approaches to modulate the elements and magnitude ofthese responses; and evaluate the impact of the induced innate responses on the generation of Yersinia)estis F1 and V antigen specific antibodies. Although the measurement of IgG titers against Y. pestis F1]nd V antigens is of obvious importance in assessing the efficacy of flagellin and the viral vaccine vectors,we believe that it is essential to determine the quality of the memory immune response in terms of its abilityto protect animals against challenge with Y. pestis. Therefore, we propose to establish an Animal ChallengeCore Laboratory of the Program, that will provide a uniform and consistent animal model for cross-evaluationof vaccine and adjuvant efficacy. The Core will have the following aims:
Specific Aim 1. To provideconsistent, high quality BSL3 reagents that are needed for the evaluation of adjuvants and vaccines. The Y._estis wild-type CO92, originally isolated from the sputum of a human case of pneumonic plague, will beJsed in the challenge studies. The Core will prepare frozen stocks of the bacteria and will maintained themat -80C and will prepare standardized doses of the bacteria for experiments.
Specific Aim 2. To performuniform and consistent challenge experiments using Y. pestis strain CO92 in mice. A critical aspect of thework in Projects 1-3 will be to test the efficacy of various immunization protocols using flagellin as anadjuvant or SV5 or VSV as vaccine vectors for the F1/V fusion protein. The Core will establish areproducible challenge model in BALB/c mice. The mice will be immunized with the F1/V fusion proteinaccording to the protocols established in Projects 1-3 and then will subject the mice to challenge with Y.pestis CO92 using s.c. injection or a nose-only inhalation exposure system (CH Technologies, Inc.).Measurements will include survival and bacterial burden in the lungs and spleen of animals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI060642-05
Application #
7640913
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2008-07-01
Project End
2009-06-30
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
5
Fiscal Year
2008
Total Cost
$95,439
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Beauchamp, Nicole M; Yammani, Rama D; Alexander-Miller, Martha A (2012) CD8 marks a subpopulation of lung-derived dendritic cells with differential responsiveness to viral infection and toll-like receptor stimulation. J Virol 86:10640-50
Clark, Kimberly M; Johnson, John B; Kock, Nancy D et al. (2011) Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge. Virology 419:97-106
Bates, John T; Graff, Aaron H; Phipps, James P et al. (2011) Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88. J Immunol 186:6255-62
Ahmed, Maryam; Puckett, Shelby; Arimilli, Subhashini et al. (2010) Stimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin. J Virol 84:12093-8
Manuse, Mary J; Briggs, Caitlin M; Parks, Griffith D (2010) Replication-independent activation of human plasmacytoid dendritic cells by the paramyxovirus SV5 Requires TLR7 and autophagy pathways. Virology 405:383-9
Beauchamp, Nicole M; Busick, Rhea Y; Alexander-Miller, Martha A (2010) Functional divergence among CD103+ dendritic cell subpopulations following pulmonary poxvirus infection. J Virol 84:10191-9
Braxton, Cassandra L; Puckett, Shelby H; Mizel, Steven B et al. (2010) Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J Virol 84:3552-61
Mizel, Steven B; Bates, John T (2010) Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 185:5677-82
Delaney, Kristen N; Phipps, James P; Johnson, John B et al. (2010) A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol 23:201-10
Palmer, Ellen M; Holbrook, Beth C; Arimilli, Subhashini et al. (2010) IFNgamma-producing, virus-specific CD8+ effector cells acquire the ability to produce IL-10 as a result of entry into the infected lung environment. Virology 404:225-30

Showing the most recent 10 out of 25 publications